Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(1 year, 12 days from now) | |
US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(2 years from now) | |
US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6488962 | BOEHRINGER INGELHEIM | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(3 years ago) | |
US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(8 months ago) | |
US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(8 months ago) | |
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(1 year, 6 months from now) | |
US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(1 year, 7 months from now) | |
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(2 years from now) | |
US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(4 years from now) | |
US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(4 years from now) | |
US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(4 years from now) | |
US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(5 years from now) | |
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(5 years from now) | |
US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(6 years from now) | |
US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(6 years from now) | |
US11564886 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(7 years from now) | |
US10596120 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(7 years from now) | |
US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(10 years from now) | |
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(10 years from now) |
Market Authorisation Date: 27 January, 2020
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes using a pharmaceutical composition comprisi...
Dosage: TABLET, EXTENDED RELEASE;ORAL